proteomics

3 downloads 0 Views 4MB Size Report
Nicola Ternette, Marloes J. M. Olde Nordkamp, Julius Müller,. Amanda P. Anderson, Annalisa Nicastri, Adrian V. S. Hill, Benedikt M. Kessler and Demin Li.
These are not the final page numbers

PROTEOMICS Supporting Information for Proteomics DOI 10.1002/pmic.201700465 Nicola Ternette, Marloes J. M. Olde Nordkamp, Julius M¨ uller, Amanda P. Anderson, Annalisa Nicastri, Adrian V. S. Hill, Benedikt M. Kessler and Demin Li Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens

C

2018 The Authors. Proteomics Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

www.proteomics-journal.com

Figure 1. Supporting Information Figure S1

Patient 4

HLA-A2 positive sample

Patient 7

HLA-A2 negative sample

Patient 8

HLA-A2 positive sample with tumourial HLA-A2 downregulation

Supporting Information Figure S2 A

Length distribution 0.6

P1 N P1 T

0.4

B

Charge state 0.8 0.6

P1 N P1 T

Normal (N) 2.0

0.2

2.0

L V

L P

V I

A

R

D

0.0

0.6

0.8

2.0

0.4

0.6

P2 N P2 T

0.4 0.2

K

1

P3 N P3 T

0.4

0.6

P3 N P3 T

0.4 0.2

A

0.6

P4 N P4 T

0.4

0.6

1

P4 N P4 T

0.2

Y

L Y

7

I I ER E V S G P F T P N

8

9

V L

L

Y I

E

V

S

T T

Q

L

A

G R

L

L

N

D

3

4

6

5

7

8

9

L

Y F

L

V

A

0.0

V

K A

A

L

Y

I M T

A

E

L

T

V

G

L

I

T S

I

A

K

E

S M

F

V

V

N

H S

T

L

Q R

P

G

2

3

4

M N T V

1

2

3

Y

4

6

5

7

8

9

L

A

P Y

D V

I

S A

6

5

7

0.0

8

K E RV

9

A K

L

S TF

V L A

T G T G L A

K

Q

R

I

D

Q A

G

F

H

L S S P K

K Y

F

K I

L V I

A E

DV I

L

I

M

V L

R

T

N

T

I

V E

R

L

M

N Q

R

1

2

3

5

4

6

7

8

9

V A

Y

V

V

G

S S R

G

P H

T

V

K

R

G

N

R P

E

T V

P A

K

S

A L G

M

I M W

1

2

3

4

5

6

7

8

9

A

R

K

R T

L

K I I T Q L K E

T Y

G

D I N

F

V K I

S

LS

V

Y

L V

A

F

S VP A

L T A D R

S

K

P

L

K

D

L

E

1.0

I

E

E

0.0

V

DK

A

VV L

R P I

R

T

T

S

L

A

K

K

I

T

V P K G

S

M

V

Q

A R

S

G L

L

Y

F

L

Q R V

H

1

2

3

4

5

6

7

8

9

M

A

V D T

V

P K

V

G S

S

A

T H I T

L

T

V

L

L

F

2

A

Q

G

1

M

3

K W

4

5

6

7

8

9

V M

A

0.0

S V G

F

I

D

A

V

K

T L

V

V

K

S A L

A

Q

L

H

A

Q

L

R

W

F

1

M

Q

V

S

E T

E

S G

F

Y

T I

V

D

P

L K

I

I Y

S A

E

R

A E

K

R A

K

T

E

S

L

Q

L

V

I D

S

D

L

I

L

Y

1.0

Y

E

A

I

W

E

R

R

L

M

I

LS

2.0

S

D

2

3

4

6

5

7

8

9

2.0

P6 T

0.0

peptide length [aa]

A

D Y

A H S V Q P

Q

E

T

2.0

peptide charge [+e]

L

R

K

A

RV S A

0.0

L F

E

1.0

0.2

0.0

M

A R H

1

1.0

Q

Q

1.0

0.4 0.2

K V

S E

D

K F K I Q P V R R A

S

I

0.6

0.4

M

K

R

K

M

2

R

F K

2.0

0.0

1

K

G

K L

G

T

A

P6 T

6

H

R

0.6

5

4

KV

G

0.8

Q

K

K

0.0

G Q

S

D

M

0.2

0.0

G P E

R I

E P A

0.4

A

G

N

Q

S G

A

D

I

P

K

K P P

L

0.6

V

G R

L

P5 N P5 T

A T

R VV

P

F S K I

K

S

I

F

R

D P Q E Q H A D F S T HA RK A E A P D H M M M V G N E R R RN S S S Y F T

R

0.4

L

2.0

0.0

W

S E

RD

Y

M

A

Q

S

2.0

E

0.8

A

T E

1.0

0.0

L T

Q

V

V

K L L E L T T A H GL R I S V EV H AS HFD S I

0.0

N V

G I

1.0

A LS Q

AT K

H

N L

3

I

P5 N P5 T

9

S K

2

S

0.6

T

T E

S

V

N

DL

0.2

0.0

K T

D

R

A A I

0.4 0.2

K V P G

I GV L

S R

V

L

0.8

H

S

Y

G

0.0

8

0.0

K

K

S

I

I

0.0

7

D E

A

I

M

L S Y L T G R

1.0

0.2

6

Y L

V

I

A

0.6

5

4

L Q V

2.0

M K

G

0.8

S

2.0

K

0.0

R P

K

A

D

G

G

L

3

A I

TL S

A

S Q

P

K N

2

0.2 0.0

L

V

G

A

K

S

T

E G

1.0

0.0

V

I

R

T

S

R

D Y

E T A I V

V

L

P L

V

Q

S

M

R

G

L

A

Q

N

D

Y R

V

L

G I

E

A

S T

0.0

V F

L

R V

K

W S

L

P

1.0

F

R

K

0.0

P2 N P2 T

Tumour (T)

1.0

0.4 0.2

C

L

A

I

V

L I

P

V L K P

I

N

V

E T

K A

H K

R

A Q

Y K T

Q

T

L M

L

Q S

1

2

3

4

5

6

7

R

R V

F

I

I M

S V

S

G S

M

T

E

D F

I GT E

V Y W

8

A K

Position in peptide [aa]

9

Supporting Information Figure S3 A

P1

P2

P3

P4

P5

T2

T3

T4

T5

N

T

B

T1

N2

T2

N3

T3

N4

T4

N5

N1

N2

N3

N4

Supporting Information Figure S4

*

440

478

497

492

390

960

1240

947

1117

1087

581

471

180

211

317

684

703

1478

1245

914

817

1403

957

1328

2176

1196

1653

496

Supporting Information Figure S5

1000 100 10 1 0.1 10

100

1000

10000 100000

Protein length [aa]

Supporting Information Figure S6 A

B CFL-1

CFL-1

P1 IL-32

PCNA

Syntenin-1

RPN-2

P2

P3

P4

P5

IL-32

PCNA

Syntenin-1

RPN-2